SEC-sourced researchBeta
CTKB
Cytek Biosciences, Inc.
Company comparison ↗
Data passport
- CIK
- 0001831915
- Exchange
- Nasdaq
- Business activity
- — · SIC 3826
- Financial inputs
- 6/6
- Filing date
- Sep 29, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 193,015,000.0000 | Feb 26, 2026 |
| December 2024 | 200,453,000.0000 | Feb 26, 2026 |
| December 2025 | 201,493,000.0000 | Feb 26, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 201,493,000.0000 | -66,539,000.0000 | -4,686,000.0000 | 461,542,000.0000 | 119,803,000.0000 | Feb 26, 2026 |
| December 2024 | 200,453,000.0000 | -6,020,000.0000 | 25,379,000.0000 | 499,500,000.0000 | 103,763,000.0000 | Feb 26, 2026 |
| December 2023 | 193,015,000.0000 | -12,148,000.0000 | 5,281,000.0000 | — | — | Feb 26, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $201.49M | December 2025 | Feb 26, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $200.45M | December 2024 | Feb 26, 2026 | 10-K |
| Net incomeProfitLoss | -$66.54M | December 2025 | Feb 26, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$4.69M | December 2025 | Feb 26, 2026 | 10-K |
| Total assetsAssets | $461.54M | December 2025 | Feb 26, 2026 | 10-K |
| Total liabilitiesLiabilities | $119.8M | December 2025 | Feb 26, 2026 | 10-K |